Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and Mylan N.V. (NASDAQ: MYL) (TASE: MYL) today announced the development strategy for M710, a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Momenta Pharmaceuticals (MNTA) PT Raised to $15 at Stifel Following Positive M281 MAD Data, EYLEA Biosimilar UnveilingJanuary 5, 2018 12:40 PM Mylan (MYL) PT Raised to $44 at BofA/Merrill Lynch Following Generic Estrace Cream Approval January 4, 2018 8:08 AM Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)January 3, 2018 4:05 PM